📈 Jumpstart Signal Watchlist — September 23, 2026

🏢 What they do: Paysign, Inc. is a payments technology company that provides prepaid card programs, integrated payment processing, and digital banking/payment solutions for businesses, healthcare and pharmaceutical clients, and government or consumer payout programs.
- 🎯 Current $12.67 is 10% below 3yr high $14.14 · ⏳ SMA200 $7.04 (current price $12.67 is above) · 💰 Market Cap $715M
- PAYS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 49/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 450% (>20%); Revenue growth 48% (>15%); ROE 26% (>15%); Low LT D/E 0.06 (<1.0).
⏰ Entry (E): 0/20
- 📈 RSI at 52 in healthy mid-range
📢 Sentiment (S): 7/10
- 🗞️ News sentiment is positive (✅×2 ⚪️×3; showing 4 of 5).
✅ Paysign (NASDAQ:PAYS) Shares Down 5.3% - MarketBeat — MarketBeat.
🤖 This article is positive because it notes continued analyst support, including a consensus Buy rating and multiple buy recommendations/price targets. That analyst backdrop is favorable even though some of the content is older context.
✅ Paysign (PAYS) Upgraded to Buy: What Does It Mean for the Stock? — Yahoo Finance.
🤖 The article highlights a Buy upgrade from Zacks, which is generally supportive for sentiment. It does not discuss a negative fundamental development, so the net read is positive.
⚪️ Paysign EVP, operations Joan Herman sells $716,899 in shares — Investing.com.
🤖 This is an insider sale, which is generally backward-looking and not a direct operational catalyst. The article also mentions Paysign’s strong recent quarterly results and raised outlook, but the sale itself is neutral for the stock.
⚪️ Paysign chief innovation officer Michael Ngo sells $1.9m in stock — Investing.com.
🤖 This is another insider selling report, which by itself is not a directional business catalyst. The article includes context about Paysign’s strong second-quarter results and raised full-year outlook, but the filing itself is neutral.
🍭 Bonus (B): 0/10 — Business Services

🏢 What they do: Vir Biotechnology is a clinical-stage biopharmaceutical company that develops medicines for serious infectious diseases and cancer. Its work centers on immune-based therapies, including antibody-based and other platform-driven drug candidates such as programs for hepatitis delta, hepatitis B, and solid tumors.
- 🎯 Current $11.09 is 12% below 3yr high $12.66 · ⏳ SMA200 $8.81 (current price $11.09 is above) · 💰 Market Cap $1.9B
- VIR shows decent technicals supported by positive sentiment.

💎 Quality (Q): 32/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 159% (>20%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive (✅×4 ⚪️×1; showing 3 of 5).
✅ Vir Biotechnology stock hits 52-week high at 11.66 USD — Investing.com.
🤖 VIR reached a 52-week high after reporting a stronger cash position and a quarterly swing to net income, aided by an Astellas collaboration payment. The article also noted H.C. Wainwright reaffirmed a Buy rating and $20 target based on progress in hepatitis D programs.
✅ Vir Biotechnology (NASDAQ:VIR) Sets New 52-Week High — MarketBeat.
🤖 The stock reached a new 52-week high, while the article highlighted Vir's second-quarter EPS and revenue beats versus consensus estimates. Although it notes ongoing unprofitability on a broader basis, the reported earnings surprise and share-price milestone are favorable near-term signals.
⚪️ Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference — Business Wire.
🤖 Vir announced that its CEO would participate in an investor-conference fireside chat. This is an investor-relations event announcement without new financial results, guidance, clinical data, or a rating change, so it is neutral for the stock.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Red Violet, Inc. provides identity intelligence software and data solutions for identity verification, fraud detection and prevention, risk mitigation, investigations, due diligence, customer acquisition, and asset recovery. Its products include idiCORE and FOREWARN.
- 🎯 Current $76.20 is 2% below 3yr high $77.52 · ⏳ SMA200 $53.86 (current price $76.20 is above) · 💰 Market Cap $1.1B
- RDVT shows decent technicals supported by positive sentiment.

💎 Quality (Q): 54/60
- 🏦 Low drawdown (13.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 89% (>20%); Revenue growth 23% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ Red Violet (NASDAQ:RDVT) Upgraded at Zacks Research — MarketBeat.
🤖 Zacks Research upgraded Red Violet from Hold to Strong Buy. The article also cited quarterly EPS and revenue that exceeded analyst expectations, supporting a positive view of the stock.
✅ Red Violet (RDVT) Expands FOREWARN Reach Through This Latest Partnership — Yahoo Finance.
🤖 Red Violet’s FOREWARN subsidiary partnered with the Pacific West Association of REALTORS, extending its identity-verification and safety solutions to more than 10,000 members. The expanded distribution could support customer and revenue growth.
✅ Red Violet (NASDAQ:RDVT) Raised to "Moderate Buy" at Raymond James Financial — MarketBeat.
🤖 Raymond James raised Red Violet to a Moderate Buy rating, adding to favorable analyst coverage. The report also noted the company’s quarterly earnings and revenue beat.
🍭 Bonus (B): 10/10 — Prepackaged Software (Technology sector)

🏢 What they do: CareDx, Inc. is a precision medicine company focused on transplant patients. It develops diagnostics, digital health tools, lab products, and patient support services to help monitor care before and after organ transplantation.
- 🎯 Current $54.31 is 4% below 3yr high $56.49 · ⏳ SMA200 $27.14 (current price $54.31 is above) · 💰 Market Cap $2.8B
- CDNA shows decent technicals supported by positive sentiment.

💎 Quality (Q): 59/60
- 🏦 Low drawdown (12.3% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 1394% (>20%); Revenue growth 52% (>15%); ROE 26% (>15%).
⏰ Entry (E): 2/20
- 🔔 Strong above EMA21 (5.4%)
- 🔔 Strong above EMA50 (18.1%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 65 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ CareDx, Inc. (NASDAQ:CDNA) Receives Consensus Rating of "Moderate Buy" from Brokerages — MarketBeat.
🤖 CareDx retains a Moderate Buy consensus rating, and Canaccord Genuity initiated coverage with a Buy rating and a $65 price target. The article also cites prior earnings that exceeded expectations, supporting a positive view, although the publication date is September 23, 2026.
✅ CareDx (NASDAQ:CDNA) Reaches New 52-Week High - Still a Buy? — MarketBeat.
🤖 CareDx shares reached a new 52-week high of $55.21, while the article highlights broadly positive analyst sentiment and recent quarterly results that exceeded expectations. Insider selling is a counterpoint but does not outweigh the reported earnings and analyst catalysts.
✅ Caredx Inc stock hits 52-week high at 55.21 USD — Investing.com.
🤖 The article reports stronger-than-expected second-quarter 2026 adjusted EPS and revenue, along with a raised full-year outlook. Revenue grew approximately 52% year over year and testing revenue rose 61%, providing a positive fundamental catalyst.
🍭 Bonus (B): 0/10 — Medical Laboratories

🏢 What they do: Five9, Inc. provides cloud contact center software, including its Intelligent CX platform for managing customer interactions across voice and digital channels like chat, email, SMS, and social media. Its products also include AI, automation, analytics, and workforce optimization tools that help businesses run customer service and sales operations.
- 🎯 Current $37.68 is 56% below 3yr high $85.47 · ⏳ SMA200 $22.10 (current price $37.68 is above) · 💰 Market Cap $2.8B
- FIVN shows decent technicals supported by positive sentiment.

💎 Quality (Q): 45/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 300% (>20%); Low LT D/E 0.25 (<1.0); PEG ratio 0.18 (<1.5).
⏰ Entry (E): 4/20
- 🔔 Strong above EMA21 (11.8%)
- 🔔 Strong above EMA50 (21.4%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 64 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ Five9 (NASDAQ:FIVN) Shares Up 8.7% After Analyst Upgrade — MarketBeat.
🤖 Cantor Fitzgerald raised its price target on Five9 from $34 to $40 and kept an overweight rating, which is a bullish analyst signal. The article also notes Five9’s recent quarterly results beat expectations, supporting a positive stock reaction.
✅ FBN Securities Upgrades Five9 (NASDAQ:FIVN) to "Strong-Buy" — MarketBeat.
🤖 FBN Securities upgraded Five9 to strong buy, adding another favorable analyst call. The article also references the company’s earnings beat and revenue growth, which reinforce a constructive view of the stock.
✅ Cantor Fitzgerald Boosts Five9 (NASDAQ:FIVN) Price Target to $40.00 — MarketBeat.
🤖 This is a positive analyst-action article because Cantor Fitzgerald lifted its target to $40 and reiterated an overweight rating. The piece ties the upgrade to Five9’s stronger-than-expected quarterly results and improving fundamentals.
🍭 Bonus (B): 10/10 — Computer Processing & Data Prep (Technology sector)

🏢 What they do: DexCom, Inc. is a medical device company that develops and sells continuous glucose monitoring (CGM) systems for people with diabetes. Its products, including the Dexcom G6 and G7, use wearable sensors and mobile apps to track glucose levels in real time and help users manage their blood sugar.
- 🎯 Current $87.73 is 38% below 3yr high $140.45 · ⏳ SMA200 $72.19 (current price $87.73 is above) · 💰 Market Cap $33.1B
- DXCM shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (14.0% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 42% (>20%); ROE 38% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 2/20
- 📈 RSI at 52 in healthy mid-range
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive (✅×4 ⚪️×1; showing 3 of 5).
✅ Dexcom Promotes Jereme Sylvain to Chief Operating Officer — Business Wire.
🤖 DexCom promoted its CFO, Jereme Sylvain, to COO as well, signaling confidence in leadership continuity and execution. The same source page also references other corporate updates, but the COO promotion is the relevant news item here.
✅ Dexcom at Wells Fargo conference: coverage push drives growth plan — Investing.com.
🤖 At its conference presentation, DexCom outlined a growth plan centered on broader insurance coverage, new products, and margin expansion. The article also notes longer-term Medicare coverage potential, which could support future growth, though there are some near-term headwinds.
⚪️ DexCom Appoints Glenn Boehnlein to Board of Directors — Business Wire.
🤖 DexCom appointed Glenn Boehnlein to its board of directors. This is a corporate governance update, but it does not by itself provide a clear operating catalyst for the stock.
🍭 Bonus (B): 0/10 — Surgical & Medical Instruments

🏢 What they do: ScanSource is a technology distributor that connects hardware, software, connectivity, and cloud solutions to channel partners and businesses. Its products and services include point-of-sale systems, barcode and data-capture equipment, networking, communications, physical security, payments, and related value-added services.
- 🎯 Current $58.48 is 1% below 3yr high $58.89 · ⏳ SMA200 $45.12 (current price $58.48 is above) · 💰 Market Cap $1.2B
- SCSC shows decent technicals supported by positive sentiment.

💎 Quality (Q): 55/60
- 🏦 Low drawdown (12.7% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 40% (>20%); Revenue growth 17% (>15%); Low LT D/E 0.38 (<1.0).
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive (✅×5; showing 3 of 5).
✅ ScanSource (SCSC) Momentum Run Keeps Fair Value In Focus — Yahoo Finance.
🤖 The article highlights ScanSource's strong share-price momentum, including gains of approximately 10.6% over the past month and 45.6% year to date. It presents the momentum and improving investor reassessment as supportive of the stock, while noting fair-value considerations.
✅ ScanSource (SCSC) Shows Fast-paced Momentum But Is Still a Bargain Stock — Yahoo Finance.
🤖 The article characterizes ScanSource as having rapid price momentum while still appearing attractively valued. That combination could support further investor interest and is positive for the stock.
✅ ScanSource (SCSC) Bets $220M On A Bigger IT Footprint — Yahoo Finance.
🤖 The article discusses ScanSource's September 2 completion of its $220.5 million all-cash acquisition of MicroAge. The transaction expands ScanSource's IT footprint and is expected to be accretive to margins, non-GAAP EPS, and free cash flow, making it a positive strategic catalyst.
🍭 Bonus (B): 0/10 — Computers & Software - Wholesale